02396nas a2200457   4500000000100000008004100001260001300042653001500055653001000070653000900080653002600089653002400115653001000139653001200149653003100161653003000192653001100222653001600233653001100249653002100260653002100281653002300302653002400325653002500349653002400374653000900398653001600407653002500423653001300448100001400461700001600475700001600491700001600507700001800523245008000541856004100621300001000662490000700672520124500679022001401924       1993                            d  c1993 Mar10aAdolescent10aAdult10aAged10aAntibodies, Bacterial10aAntigens, Bacterial10aChild10aDapsone10aDrug Resistance, Microbial10aDrug Therapy, Combination10aFemale10aGlycolipids10aHumans10aImmunoglobulin G10aImmunoglobulin M10aLeprostatic Agents10aLeprosy, Borderline10aLeprosy, lepromatous10aLipopolysaccharides10aMale10aMiddle Aged10aMycobacterium leprae10aRifampin1 aRoche P W1 aBritton W J1 aFailbus S S1 aNeupane K D1 aTheuvenet W J00aSerological monitoring of the response to chemotherapy in leprosy patients.  uhttp://ila.ilsl.br/pdfs/v61n1a07.pdf  a35-430 v613 a<p>Sixty-five patients initially seropositive for IgM anti-phenolic glycolipid-I (PGL-I) antibodies were tested for antibody levels to PGL-I, lipoarabinomannan (LAM), and the 35-kDa protein of Mycobacterium leprae at regular intervals for up to 30 months following the commencement of multidrug therapy (MDT). There was a steady decline in IgM anti-PGL-I and anti-35-kDa antibody levels to a mean of 17% and 14%, respectively, of the starting level at 24 months. The development of type 1 and type 2 reactions or the presence of drug-resistant organisms in a small number of patients had no significant influence on the changes in antibody level. The rate of decline was similar in different disease categories, but a higher proportion of lepromatous patients remained seropositive at the end of 2 years of treatment than borderline tuberculoid patients. By contrast, the mean IgG anti-LAM antibody levels remained stable or increased. Again the occurrence of type 1 or type 2 reactions had no significant effect on antibody level over 2 years. Falls in the IgM anti-PGL-I antibody levels mirrored the falls in the bacterial index in individual patients and provide an additional parameter for monitoring the response to chemotherapy.</p>
  a0148-916X